Publications by authors named "Fernando Lopez-Calderon"

Background: Fascin1 is the key actin-bundling protein involved in cancer invasion and metastasis whose expression is associated with bad prognosis in tumor from different origins.

Methods: In the present study, virtual screening (VS) was performed for the search of Fascin1 inhibitors and RAL, an FDA-approved inhibitor of human immunodeficiency virus-1 (HIV-1) integrase, was identified as a potential Fascin1 inhibitor. Biophysical techniques including nuclear magnetic resonance (NMR) and differential scanning fluorimetry (DSF) were carried out in order to confirm RAL as a Fascin1 blocker.

View Article and Find Full Text PDF

Serrated adenocarcinoma (SAC) is a tumor recognized by the WHO as a histological subtype accounting for around 9% of colorectal carcinomas. Compared to conventional carcinomas, SACs are characterized by a worse prognosis, weak development of the immune response, an active invasive front and a frequent resistance to targeted therapy due to a high occurrence of KRAS or BRAF mutation. Nonetheless, several high-throughput studies have recently been carried out unveiling the biology of this cancer and identifying potential molecular targets, favoring a future histologically based treatment.

View Article and Find Full Text PDF
Article Synopsis
  • - Serrated adenocarcinoma (SAC) is more aggressive than conventional colorectal carcinoma (CRC) and shows resistance to certain treatments, particularly due to the overexpression of a protein called fascin1, which aids in tumor invasion.
  • - Researchers conducted a screening of over 9,500 compounds, identifying the FDA-approved antidepressant imipramine as a potential inhibitor of fascin1, demonstrating its effectiveness through various biophysical tests.
  • - Imipramine showed promising anti-invasive properties in lab-cultured colorectal cancer cells and in a zebrafish model, indicating its potential as a targeted therapy for SAC and other related tumors.
View Article and Find Full Text PDF
Article Synopsis
  • Bladder cancer is particularly deadly in its advanced stages, and recent research has identified new genetic targets and emphasized the limited effectiveness of current treatments, especially immune checkpoint inhibitors.
  • The study highlights how high levels of G9a (EHMT2) expression correlate with worse outcomes and shows that a novel inhibitor, CM-272, can induce cancer cell death and boost immune response when combined with traditional chemotherapy.
  • The combination of CM-272 with immune checkpoint inhibitors demonstrates significant tumor regression and improved immune reactions in a mouse model, suggesting new strategies for treating bladder cancer by pairing epigenetic therapies with immunotherapy.
View Article and Find Full Text PDF
Article Synopsis
  • * Lab tests on bladder cancer cell lines showed sensitivity to CDK4/6 inhibitors and identified FOXM1 as a key player in the cancer's response, with the inhibitors reducing FOXM1 phosphorylation and enhancing the effectiveness of cisplatin.
  • * The study suggests that CDK4/6 inhibitors, individually or in combination with cisplatin, could offer a promising new treatment option for patients with advanced bladder cancer who are not suitable for existing therapies.
View Article and Find Full Text PDF

Bladder cancer is a current clinical and social problem. At diagnosis, most patients present with nonmuscle-invasive tumors, characterized by a high recurrence rate, which could progress to muscle-invasive disease and metastasis. Bone morphogenetic protein (BMP)-dependent signaling arising from stromal bladder tissue mediates urothelial homeostasis by promoting urothelial cell differentiation.

View Article and Find Full Text PDF

The high rates of tumor recurrence and progression represent a major clinical problem in non-muscle invasive bladder cancer. Previous data showed that EZH2-dependent signaling mediates these processes, whereas the frequent alterations of PIK3CA gene (copy gains and mutations) are predictive of reduced recurrence. Here we show, using clinical samples and bladder cancer cell lines, a functional interaction between EZH2- and PIK3CA-dependent signaling pathways.

View Article and Find Full Text PDF

Bladder Cancer (BC) represents a current clinical and social challenge. The recent studies aimed to describe the genomic landscape of BC have underscored the relevance of epigenetic alterations in the pathogenesis of these tumors. Among the epigenetic alterations, histone modifications occupied a central role not only in cancer, but also in normal organism homeostasis and development.

View Article and Find Full Text PDF

Bladder cancer (BC) is a highly prevalent disease, ranking fifth in the most common cancers worldwide. Various miRNAs have recently emerged as potential prognostic biomarkers in cancer. The miR-200 family, which repressed the epithelial-to-mesenchymal transition (EMT), is repressed in multiple advanced cancers.

View Article and Find Full Text PDF

Background: Long non-coding RNAs (lncRNAs) have been claimed as key molecular players in gene expression regulation, being involved in diverse epigenetic processes. They are aberrantly expressed in various tumors, but their exact role in bladder cancer is still obscure. We have recently found a major role of the Polycomb repression complex in recurrence of non-muscle-invasive bladder cancer.

View Article and Find Full Text PDF

The TP63 gene codes for two major isoform types, TAp63 and ΔNp63, with probable opposite roles in tumorigenesis. The ΔNp63α protein is frequently amplified and overexpressed in different epithelial tumors. Accordingly, it has been considered a potential oncogene.

View Article and Find Full Text PDF